KRAS and colorectal carcinoma: However, in cohorts receiving adagrasib in combination with cetuximab, the objective response rate increased to 46%, with a median duration of response of 7.6 months, and a PFS of 6.9 months.381,382 The FDA granted breakthrough therapy designation for adagrasib in combination with cetuximab for the treatment of patients with KRAS-G12C CRC in December 2022.